The Food and Drug Administration has revised its provider and recipient fact sheets for the Johnson & Johnson COVID-19 vaccine due to reports of immune thrombocytopenia (ITP), a disorder that can cause easy or excessive bruising and bleeding due to very low platelet levels. According to the recipient fact sheet, the chance of ITP is “very low,” with symptoms in most cases occurring within 42 days after vaccination. FDA said it continues to monitor the level of potential excess risk with the Centers for Disease Control and Prevention. Individuals with a history of ITP should discuss the risk with their health care provider and the potential need for platelet monitoring after vaccination, the fact sheets note. 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services today released updated interpretive guidance on its Omnibus COVID-19 Health Care Staff Vaccination…
Blog
To help hospitals and health system leaders stay up-to-date on all of the legal developments related to vaccine mandates, the AHA has developed a blog…
Headline
Leaders from the AHA and the American College of Obstetricians and Gynecologists, hospital leaders, clinicians and experts from the Centers for Disease Control…
Headline
A new AHA video is tackling prominent myths about COVID-19 and its vaccines, providing the public with the facts they need to make sound health decisions…
Headline
In addition to the seven new 2022 ICD-10 procedure codes announced in November, the Centers for Medicare & Medicaid Services on April 1 will implement…
Headline
The Centers for Medicare & Medicaid Services has approved a new Healthcare Common Procedure Coding System code J0248 for the VEKLURY (remdesivir) antiviral…